The fixed-dose combination is indicated for the treatment of early breast cancer (EBC): * Use in combination with chemotherapy for: * the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than twocm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; * the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence. and for the treatment of metastatic breast cancer (MBC): * Use in combination with docetaxel for the treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Pertuzumab/trastuzumab/hyaluronidase
Trastuzumab/hyaluronidase
Daratumumab/hyaluronidase
Bortezomib/dexamethasone
Loncastuximab tesirine
Decitabine/cedazuridine
Trastuzumab emtansine
Trifluridine/tipiracil